Vanguard Group Inc. Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Vanguard Group Inc. lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.4% in the fourth quarter, HoldingsChannel reports. The firm owned 15,596,480 shares of the biopharmaceutical company’s stock after purchasing an additional 209,190 shares during the quarter. Vanguard Group Inc. owned 0.10% of TG Therapeutics worth $469,454,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TGTX. State Street Corp increased its holdings in shares of TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock worth $38,212,000 after acquiring an additional 84,904 shares during the last quarter. Bank of New York Mellon Corp raised its position in TG Therapeutics by 10.5% during the fourth quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock valued at $27,797,000 after purchasing an additional 87,679 shares during the period. Principal Financial Group Inc. lifted its stake in shares of TG Therapeutics by 7.5% in the 4th quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company’s stock valued at $24,989,000 after purchasing an additional 57,996 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after purchasing an additional 270,286 shares during the period. Institutional investors own 58.58% of the company’s stock.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on TGTX. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $37.75 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market cap of $5.93 billion, a price-to-earnings ratio of -377.46 and a beta of 2.30. The firm has a 50-day moving average of $34.73 and a two-hundred day moving average of $30.60. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.